World Health Organization warns! “Remdesivir” should not be used for COVID-19 because there is no conclusive evidence that Treatment of COVID-19
November 20, 2020, Xinhua news agency reported that World Health Organization (WHO) warned that Remdesivir, an antiviral drug, should not be used to treat patients.New coronavirus disease (COVID-19) No matter how serious the patient is Because there is no conclusive evidence that This drug can be used to treat such ailments.
The WHO Guideline Development Group (GDG) said its experts had not found enough evidence to indicate Remdecivir could help treat COVID-19. Both in reducing the mortality rate Reduces the need for a ventilator Shorten clinical and other treatment time, provided that the positive effects of Remdecivir use exist. Is low and there is still a potential danger of using this drug.
Eight countries found, no COVID-19 reported While the world over 57 million
Traction out of state, California announced. “Curfew” to block the coronavirus crisis
Nearly 1 million Chinese people have been vaccinated against COVID-19.
COVID peaks on 20 Nov 20, with 4 new cases from three countries.
Advice of the Organization Which is published in the British Medical Journal (British Medical Journal) based on a review of evidence. This includes data from four randomized international trials involving more than 7,000 hospitalized patients.
After conducting a review of the evidence, the group concluded that Yarem DesivirIt did not have a positive effect on mortality or other significant outcomes for patients, especially considering the costs and resources associated with this drug. Made an opinion that There should be evidence of the efficacy of this drug. Which is still not found from the current information
This Yarem Desivir It is one of two drugs approved to treatPatients with COVID-19 Worldwide, with permission in the US, EU and other countries. After initial research, it was found that The drug may partially shorten the recovery time of COVID-19 patients for Yarem Desivir this It was developed by US company Gilead (Gilead). Which is very expensive and has to be injected into a vein, said Gillied that Remdecivier. It helped boost the company’s third-quarter sales of approximately US $ 900 million (about 2.7 billion baht).